
|Articles|July 1, 2007
Lightening up: Other options
National report - With no indication when the Food and Drug Administration (FDA) will decide on its proposed rule essentially banning all hydroquinone products that have not undergone the new drug approval process, dermatologists and patients are seeking alternatives.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 Data Position Zasocitinib as a Potential New Oral Option for Psoriasis
2
FDA Clears IND Application of Recludix’s Oral STAT6, REX-8756
3
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
4
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
5

















